12:01 EST Sarepta (SRPT) falls 10% to $21.37 after reporting preliminary Q4 revenue
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta submits clinical trial application for study SRP-1005-101 to Medsafe
- Sarepta Therapeutics Extends Debt Maturities with New Notes
- HHS adds Duchenne muscular dystrophy to recommended screening panel
- Vertiv, Affirm, Sarepta, Micron, PepsiCo: Trending by Analysts
- Sarepta put volume heavy and directionally bearish